These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28554223)

  • 21. In-vitro maturation of oocytes vs in-vitro fertilization with a gonadotropin-releasing hormone antagonist for women with polycystic ovarian syndrome: can superiority be defined?
    Shavit T; Ellenbogen A; Michaeli M; Kartchovsky E; Ruzov O; Shalom-Paz E
    Eur J Obstet Gynecol Reprod Biol; 2014 Aug; 179():46-50. PubMed ID: 24965979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In-vitro maturation versus IVF with GnRH antagonist for women with polycystic ovary syndrome: treatment outcome and rates of ovarian hyperstimulation syndrome.
    Das M; Son WY; Buckett W; Tulandi T; Holzer H
    Reprod Biomed Online; 2014 Nov; 29(5):545-51. PubMed ID: 25262236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severe ovarian hyperstimulation syndrome after combined GnRH-agonist and low-dose human chorionic gonadotropin trigger in a patient with a single kidney.
    Pereira N; Lekovich JP; Kligman I; Rosenwaks Z
    Gynecol Endocrinol; 2017 Aug; 33(8):593-597. PubMed ID: 28440686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathophysiology, treatment and prevention of ovarian hyperstimulation syndrome.
    Kwik M; Maxwell E
    Curr Opin Obstet Gynecol; 2016 Aug; 28(4):236-41. PubMed ID: 27273307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
    Şükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoğlu CS
    Reprod Biomed Online; 2017 Jan; 34(1):5-10. PubMed ID: 27771155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
    Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
    Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Day care management of severe ovarian hyperstimulation syndrome avoids hospitalization and morbidity.
    Shrivastav P; Nadkarni P; Craft I
    Hum Reprod; 1994 May; 9(5):812-4. PubMed ID: 7929727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The diagnosis and management of ovarian hyperstimulation syndrome.
    Shmorgun D; Claman P;
    J Obstet Gynaecol Can; 2011 Nov; 33(11):1156-1162. PubMed ID: 22082791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ovarian hyperstimulation syndrome--prevention and treatment].
    Grønlund LA; Bogstad JW
    Ugeskr Laeger; 1996 Dec; 158(50):7205-9. PubMed ID: 9012033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ovarian hyperstimulation syndrome: A review for emergency clinicians.
    Timmons D; Montrief T; Koyfman A; Long B
    Am J Emerg Med; 2019 Aug; 37(8):1577-1584. PubMed ID: 31097257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RANZCOG CREI Consensus Statement on treatment of Ovarian Hyperstimulation Syndrome.
    Kwik M; Karia S; Boothroyd C
    Aust N Z J Obstet Gynaecol; 2015 Oct; 55(5):413-9. PubMed ID: 26279582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases.
    Nikolettos N; Asimakopoulos B; Simopoulou M; al-Hasani S
    In Vivo; 2003; 17(6):655-8. PubMed ID: 14758735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preventing ovarian hyperstimulation syndrome: guidance for the clinician.
    Humaidan P; Quartarolo J; Papanikolaou EG
    Fertil Steril; 2010 Jul; 94(2):389-400. PubMed ID: 20416867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases.
    Gurbuz AS; Gode F; Ozcimen N; Isik AZ
    Reprod Biomed Online; 2014 Nov; 29(5):541-4. PubMed ID: 25246114
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation.
    Dahan MH; Tannus S; Seyhan A; Tan SL; Ata B
    Gynecol Endocrinol; 2018 Mar; 34(3):252-255. PubMed ID: 29057693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.